reference/1128345

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1128345

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't\|Webcast
endingPage	781
issn	1470-2045
issueIdentifier	8
pageRange	773-781
publicationName	The Lancet. Oncology
startingPage	773
bibliographicCitation	Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):773–81. doi: 10.1016/s1470-2045(12)70270-x. PMID: 22805291.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3753a2f7e9b9e49c506ac08ee3e9e7d8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ecb148721ca8d3ea4d7ec352d6ef364 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d3f194fa4ccb09034d11621b30130888 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_25b20ac33314b2c738ccf01773a2da16 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf8ada54f0f7def219f8610bf209dcfe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7c3924f957597955d324f4ad7ba94f2a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9d531eaa1df40fa5182644c52e5e6c4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_706d8fa975916df276f6555c537b61a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc16144f3b3c2e86d993395dc82f6d5c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c22b38f2532c87c617db9ebe66c0c8a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffc44959c4f4051fd10e042e30b0d8aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d6f51cb2f0ec983119a108ca80dbc84 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef32d4634a99cd8c5e8361a0f0c011cd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8a258b4c0f450cf0f3cbc2e3b9d2e586 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ceff10310bc1fce513473f9ea57551f0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78a4bea93cc6d52a199f060f7bdfdf8d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27d23e34738b1433fc80421a488a96a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43e69dad537e1047a2fb19f8e0873086 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b2f0a4184cac41b3017ea81465bad11
date	201208
identifier	https://doi.org/10.1016/s1470-2045%2812%2970270-x https://pubmed.ncbi.nlm.nih.gov/22805291
isPartOf	https://portal.issn.org/resource/ISSN/1470-2045 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
discusses	http://id.nlm.nih.gov/mesh/M0460510 http://id.nlm.nih.gov/mesh/M0460512 http://id.nlm.nih.gov/mesh/M0018261 http://id.nlm.nih.gov/mesh/M0018236 http://id.nlm.nih.gov/mesh/M0216971 http://id.nlm.nih.gov/mesh/M0575714 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0208001 http://id.nlm.nih.gov/mesh/M0001483
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6569 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11199 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e84b7754de91a1c55328ca1b83306ff8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_0a8cd9c103d72b955f0d4adf198352b8 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e38fd1cc7a5aeefeb14fe0f56b372814 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11707110 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7429 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10030 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID175427149 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5605 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5604

Total number of triples: 60.